Ltr Pharma Limited has released a press release.
Response to ASX Aware Letter
Earlier from Ltr Pharma
- LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS
- LTR Secures First U.S. Commercial Agreement for ROXUS
- SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations
- SPONTAN Phase II data show rapid onset, support FDA pathway